Chiome Bioscience Inc.
The 23rd Stock Acquisition Rights Exercise Status ｜ July 2026
As of July 21, 2026, Kyoway BioScience, Inc. exercised 14,251 shares (10.48% of the issued total) of the 23rd stock acquisition rights, resulting in an unexercised remaining of 1,498,400 shares.
Key Figures
- Number of exercised stock acquisition rights: 14,251 units (exercise ratio 10.48%)
- Remaining unexercised units: 14,984 units (1,498,400 shares)
- Number of issued shares (July 1 to 21): 1,425,100 shares
AI要約
Stock Acquisition Rights Exercise Status
This report provides a detailed account of the exercise status of the 23rd stock acquisition rights issued in December 2025 during the period from July 1 to 21, 2026. During this period, 14,251 stock acquisition rights were exercised, reaching an exercise ratio of 10.48%. Consequently, the number of issued shares amounted to 1,425,100. Meanwhile, the unexercised remaining stock acquisition rights decreased from 29,235 units at the end of the previous month to 14,984 units, indicating ongoing exercise activity. The exercise price ranged between 66.3 yen and 72.7 yen.
Impact on Shareholders and Future Outlook
The large-scale exercise of stock acquisition rights may lead to dilution of shares, but given the relatively low exercise ratio, the short-term impact on shareholder value is considered limited. Going forward, it will be important to monitor the exercise status while developing management strategies based on capital policy and funding trends. The company is expected to continue efforts toward shareholder returns and enhancing capital efficiency.
Kyoway BioScience, Inc.
Company overview · Stock price · Financial data · All IR
